CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction
Abhiram Prasad, MD, MRCP, FACC*,
Gregg W. Stone, MD, FACC ,*,
Thomas D. Stuckey, MD, FACC ,
Costantino O. Costantini, MD,
Peter J. Zimetbaum, MD, FACC ,
Michael McLaughlin, MD,
Roxana Mehran, MD, FACC,
Eulogio Garcia, MD||,
James E. Tcheng, MD, FACC¶,
David A. Cox, MD, FACC#,
Cindy L. Grines, MD, FACC**,
Alexandra J. Lansky, MD, FACC and
Bernard J. Gersh, MBChB, DPhil, FACC*
* Division of Cardiovascular Diseases and Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota
Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
Moses Cone Heart and Vascular Center, Greensboro, North Carolina
Beth Israel Deaconess Medical Center, Boston, Massachusetts
|| Hospital Gregorio Maranon, Madrid, Spain
¶ Duke Clinical Research Institute, Durham, North Carolina
# Mid Carolina Cardiology, Charlotte, North Carolina
** William Beaumont Hospital, Royal Oak, Michigan
Manuscript received September 7, 2004;
revised manuscript received October 18, 2004,
accepted October 26, 2004.
* Reprint requests and correspondence: Dr. Gregg W. Stone, The Cardiovascular Research Foundation, Columbia University Medical Center, Herbert Irving Pavilion, 5th Floor, 161 Fort Washington Avenue, New York, New York 10032 (Email: gstone{at}crf.org).
OBJECTIVES: We investigated the impact of diabetes mellitus on myocardial perfusion after primary percutaneous coronary intervention (PCI) utilizing myocardial blush grade (MBG) and ST-segment elevation resolution (STR).
BACKGROUND: Diabetes is an independent predictor of outcomes after primary PCI for acute myocardial infarction (AMI). Whether the poor prognosis is due to lower rates of myocardial reperfusion is unknown.
METHODS: Reperfusion success in those with and without diabetes mellitus was determined by measuring MBG (n = 1,301) and STR analysis (n = 700) in two substudies of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial among patients undergoing primary PCI for AMI.
RESULTS: There were no differences between those with or without diabetes with regard to postprocedural Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 (>95%), distribution of infarct-related artery, and the frequency of stent deployment or abciximab administration. Patients with diabetes mellitus were more likely to have absent myocardial perfusion (MBG 0/1, 56.0% vs. 47.1%, p = 0.01) and absent STR (20.3% vs. 8.1%, p = 0.002). Diabetes mellitus (hazard ratio [HR] 1.63 [95% confidence interval (CI) 1.17 to 2.28], p = 0.004) was an independent predictor of absent myocardial perfusion (MBG 0/1) and absent STR (HR 2.94 [95% CI 1.64 to 5.37], p = 0.005) by multivariate modeling.
CONCLUSIONS: Despite similar high rates of TIMI flow grade 3 after primary PCI in patients with and without diabetes, patients with diabetes are more likely to have abnormal myocardial perfusion as assessed by both incomplete STR and reduced MBG. Diminished microvascular perfusion in diabetics after primary PCI may contribute to adverse outcomes.
|
Abbreviations and Acronyms
| | AMI = acute myocardial infarction | | CADILLAC = Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications trial | | CI = confidence interval | | HR = hazard ratio | | MACE = major adverse cardiac events | | MBG = myocardial blush grade | | OR = odds ratio | | PCI = percutaneous coronary intervention | | STR = ST-segment resolution |
|
This article has been cited by other articles:
|
|
|
|
 
N Allou, P Piednoir, C Berroeta, S Provenchere, H Ibrahim, G Baron, P Montravers, B Iung, I Philip, and N Ajzenberg
Incidence and risk factors of early thromboembolic events after mechanical heart valve replacement in patients treated with intravenous unfractionated heparin
Heart,
October 15, 2009;
95(20):
1694 - 1700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K R Bainey, Y Fu, C B Granger, C W Hamm, D R Holmes Jr, W W O'Neill, R Seabra-Gomes, M E Pfisterer, F Van de Werf, P W Armstrong, et al.
Benefit of angiographic spontaneous reperfusion in STEMI: does it extend to diabetic patients?
Heart,
August 15, 2009;
95(16):
1331 - 1336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R Mizuno, S Fujimoto, Y Saito, and S Nakamura
Depressed recovery of subendocardial perfusion in persistent heart failure after complete revascularisation in diabetic patients with hibernating myocardium
Heart,
May 1, 2009;
95(10):
830 - 834.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lerman, D. R. Holmes, J. Herrmann, and B. J. Gersh
Microcirculatory dysfunction in ST-elevation myocardial infarction: cause, consequence, or both?
Eur. Heart J.,
April 1, 2007;
28(7):
788 - 797.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Keeley and L. D. Hillis
Primary PCI for Myocardial Infarction with ST-Segment Elevation
N. Engl. J. Med.,
January 4, 2007;
356(1):
47 - 54.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. De Luca, H. Suryapranata, J. Timmer, J. P. Ottervanger, A. W.J. van't Hof, J. C.A. Hoorntje, J.-H. Dambrink, A.T. M. Gosselink, and M.-J. de Boer
Impact of Routine Stenting on Clinical Outcome in Diabetic Patients Undergoing Primary Angioplasty for ST-Segment Elevation Myocardial Infarction
Diabetes Care,
April 1, 2006;
29(4):
920 - 923.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Prasad and B J Gersh
Management of microvascular dysfunction and reperfusion injury
Heart,
December 1, 2005;
91(12):
1530 - 1532.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Collet and G. Montalescot
The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes
Diabetes and Vascular Disease Research,
October 1, 2005;
2(3):
136 - 143.
[Abstract]
[PDF]
|
|
|
|
